Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca has completed patient enrollment in the two pivotal Phase III studies for Zactima, the company's once-daily oral anticancer drug, for the second-line treatment of non-small cell lung cancer.
Subscribe to our email newsletter
The two studies, Zodiac (Zactima in combination with docetaxel in non-small cell lung cancer) and Zeal (Zactima efficacy with alimta in lung cancer), are the second and third of four ongoing studies to complete enrollment. Data from the studies are expected later this year and the broad development program is on track for a first regulatory submission in 2008.
Zodiac and Zeal are part of a broad Phase III clinical trial program designed to gain an understanding of how Zactima (vandetanib) may benefit people with lung cancer.